Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serono Serostim Required On State Medicaid Formularies, HCFA Says

Executive Summary

State Medicaid programs are now required to include Ares-Serono's AIDS-wasting therapy Serostim in their formularies following reversal of an earlier decision by the Health Care Financing Administration.

You may also be interested in...



Serono Serostim Distribution Program To Help Reconcile Medicaid Rebates

Serono's limited distribution program for the AIDS wasting treatment Serostim will help the company reconcile its rebate payments to state Medicaid programs

Serono Serostim Distribution Program To Help Reconcile Medicaid Rebates

Serono's limited distribution program for the AIDS wasting treatment Serostim will help the company reconcile its rebate payments to state Medicaid programs

Serostim Off-Label Use Under Scrutiny; Prosecutor Looks At Job Descriptions

The Boston U.S. Attorney's Office may be looking at employee job descriptions or performance criteria in its investigations of off-label promotion

Related Content

UsernamePublicRestriction

Register

PS033990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel